Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Received a kidney transplant ≥ 9 weeks at time of Screening and ≤ 24 months before first dose~* May be the first kidney transplant or a repeat kidney transplant.~* Subjects with a functional, stable kidney transplant, defined as MDRD estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m² (chromic kidney disease stage 3 or better) at Screening.~* Men or women ≥ 18 years at the start of Screening (ie, time of informed consent).~* Corrected total serum calcium \> 10.5 mg/dL (2.63 mmol/L), defined as the mean of 2 values in Screening period.~* iPTH \> 100 pg/mL (10.6 pmol/L), during the Screening period (obtained at either Screen 1 or Screen 2).~Exclusion Criteria:~* Received cinacalcet therapy post-transplant for more than 14 days cumulatively post-transplant. If cinacalcet therapy was received for a total of 14 days or less post-transplant, there must be a 4-week washout before subject is eligible for screening (Note: This does not exclude pre-transplant use of cinacalcet).~* Anticipated parathyroidectomy within 6 to12 months after Randomization.~* Ongoing therapy with bisphosphonates or use within 6 months prior to Screening.~* Ongoing use of 1,25-dihydroxyvitamin D3 (including other active vitamin D metabolites or analogues) or use within 30 days prior to Screening.~* Ongoing use of calcium supplements or use within 30 days prior to Screening.~* Ongoing use of phosphate binders (calcium or non-calcium containing) or use within 30 days prior to Screening.~* Ongoing use of a thiazide diuretic.~* Subjects with a history of seizures who had a seizure within the 3 months prior to Randomization, which required adjustments to the seizure medication.~* Acute Kidney Injury (AKI) or renal biopsy within 6 weeks prior to Screening, unless it is an institutional protocol-driven biopsy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cinacalcet (Type: EXPERIMENTAL): Participants received cinacalcet at a starting dose of 30 mg orally once daily for 52 weeks. Cinacalcet dose was titrated every 4 weeks during the dose-titration phase and during study visits in the maintenance phase based on intact parthyroid hormone (iPTH) values, corrected total serum calcium values, and safety assessments.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo orally once daily for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).